Targeting NRF2 for the Treatment of Friedreich's Ataxia: A Comparison among Drugs.
Ontology highlight
ABSTRACT: NRF2 (Nuclear factor Erythroid 2-related Factor 2) signaling is impaired in Friedreich's Ataxia (FRDA), an autosomal recessive disease characterized by progressive nervous system damage and degeneration of nerve fibers in the spinal cord and peripheral nerves. The loss of frataxin in patients results in iron sulfur cluster deficiency and iron accumulation in the mitochondria, making FRDA a fatal and debilitating condition. There are no currently approved therapies for the treatment of FRDA and molecules able to activate NRF2 have the potential to induce clinical benefits in patients. In this study, we compared the efficacy of six redox-active drugs, some already adopted in clinical trials, targeting NRF2 activation and frataxin expression in fibroblasts obtained from skin biopsies of FRDA
SUBMITTER: Petrillo S
PROVIDER: S-EPMC6829337 | biostudies-literature | 2019 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA